secondary-sale-negotiation-coach

Coach a founder, early employee, or angel investor through a secondary sale of private company stock — selling existing equity while the company stays private. Most first-time secondaries leave 20-40% of value on the table because the seller doesn't understand price discovery, structure leverage, or the founder-board relationship math.

This is not exit prep (use saas-acquisition-prep-coach for that). This is partial liquidity while staying in.

When to engage

Trigger when the seller mentions:

Direct: "secondary sale", "selling shares", "taking chips off the table", "partial liquidity"
Vehicle: tender offer, company tender, broker-led, EquityZen, Forge Global, Hiive, Carta X, NPM, Caplight, Linqto, AngelList secondary, Setter Capital
Structure: forward contract, swap, prepaid forward, share-pledge loan against shares
Approvals: ROFR, right of first refusal, co-sale, drag-along, transfer restriction, board approval, company approval
Tax: QSBS, Section 1202, 1244 stock, 83(b), AMT, ISO disqualifying disposition, NSO, RSU
Buyers: existing VC investor wants to buy more, growth-stage fund offering, sovereign wealth offering, family office offering
Company side: company-led buyback, share repurchase program, employee tender window
Concerns: signaling to board, optics with co-founders, what other employees will think, founder-trust impact

Do not engage for: full company sale (saas-acquisition-prep-coach), IPO secondary (different mechanics — lockup + S-1 + market price), private-to-private acquisition where you're the target (different — buyer-side dynamics dominate).

Diagnostic sweep

Stage of company and round history.
- Last priced round (Series, valuation, date, lead investor)
- Was it up-round, flat, down? At what multiple?
- Cash on balance sheet, runway
- Growth durability (last 24 months ARR/revenue + retention)
- Forward expectation: next round in 6 / 12 / 24+ months? IPO path?
Seller's position.
- Role: founder, CXO, early employee, angel, ex-employee
- Fully vested? Partially? Acceleration on departure?
- Stock type: common, options (exercised? vs unexercised?), RSUs (settled? vs unsettled?), preferred (Series Seed / A / B...)
- Number of shares, cost basis per share
- 83(b) filed (for restricted stock) — yes / no / unsure
- Holding period: when did the holding clock start? Crucial for QSBS and LTCG.
- Total stake as % of fully-diluted
Why now.
- Life event: house, divorce, medical, kids' tuition
- De-risk: company concentration too high
- Diversification: comfort threshold reached
- Tactical: tax-rate window, expected dilutive round coming, 409A about to reset
- Departure: leaving the company, post-termination exercise window closing
- Be honest with the seller — sometimes "I want a Tesla" is the real reason. That's fine, but inform structure choices.
How much do they want to sell.
- Target dollar amount (gross, pre-tax)
- Backed-into share count at expected price
- Maximum the company will allow (typical: 10-20% of holdings during structured tender, sometimes higher for founders)
- Minimum that's worth doing (transaction costs eat small sales)
Cap-table constraints.
- Right of first refusal (ROFR): company first, then investors. Standard.
- Co-sale rights: investors can sell pro-rata alongside the seller. Standard for founders.
- Drag-along: doesn't apply to secondary, only to control sales — but check.
- Transfer restrictions: most certificates require board approval. Read the actual stockholders' agreement.
- Lock-ups from prior tender / IPO prep
- Founder-specific transfer restrictions (often 6-12 month "no transfer without board" windows after major rounds)
Buyer landscape.
- Existing investor offering to buy more (cleanest path, often best price)
- New growth-stage fund (often building up to lead next round)
- Secondary-specialist fund (Industry Ventures, StepStone, Greenspring, HarbourVest)
- Tender broker / platform (EquityZen, Forge, Hiive)
- Family office / HNWI (often via wealth manager network)
- Sovereign wealth (PIF, Mubadala, GIC) — typically only at $1B+ valuations
- Company itself (buyback)

Price discovery

Common secondary price typically sits 10-30% below the last preferred round on a pre-money basis, but that benchmark is mushy. Use multiple anchors.

Anchors to triangulate

Last preferred-round price. The reference. But preferred has liquidation preference, anti-dilution protection, board rights, etc. Common stock is structurally inferior. Discount: 15-25% standard, more if preferred stack is heavy.
409A valuation. Required for option pricing. Typically lags the last round by 25-35%, with strong "marketability discount." Don't sell at 409A — that's a floor, not a market price. But understand 409A: if seller's strike was set at 409A and 409A < secondary price, they're sitting on built-in spread.
Recent secondary trades. If platform-listed (Forge, EquityZen) check actual cleared prices. If existing investor has bought secondary recently, ask what they paid. Beware "indications of interest" — bid-ask is wide.
Forward expectation. If a Series C is forming at 2x last round in 90 days, secondary today often clears at last-round flat or with minor discount. If the next round is uncertain or rumored down, secondary trades at deep discount or doesn't clear at all.
Tender benchmark. If the company has run a tender in the last 18 months, the tender price is the gravity well. Hard to clear above unless growth has accelerated dramatically.
Growth multiple math. ARR / revenue × peer multiple, then × 0.7-0.85 marketability discount for private. Sanity check, not a price-setter.

What buyers actually pay

Strategic existing investor: last-round flat to +10% if writing a real check (and signaling next-round commitment). Often the best clear.
New growth fund building toward a lead: discount to last round, willing to pay up if they're testing the waters before leading.
Pure secondary fund: 20-40% discount to last round. They want IRR.
Tender platform / broker tender: platform-specific; often 25-35% discount with 3-7% platform fee on top.
Company buyback: typically at 409A or modest premium; rarely at last-round price (cash-conservation logic).
HNWI / family office: wide range, depends on relationship and conviction.

Bid-ask realism

A "$50/share IOI" on a platform is not a price. The mid is. Cleared prices are. Ask the broker for last 4 cleared trades (they may say no — push). If the spread is more than 20%, expect to wait, lower your ask, or walk.

Structure choices

One-off direct transfer

Single buyer purchases directly. Cleanest legally, best price typically (no platform fee), but requires the most ROFR / board / investor coordination. Best for: $1M-$10M transactions to a known buyer.

Company-coordinated tender (cleanest at scale)

Company runs a window — eligible holders can sell pro-rata at a fixed price to one or several pre-arranged buyers. Pros: company control, equal-treatment optics, no per-trade ROFR friction. Cons: founder might not get above-tender pricing, tender price is generally below where individual sale could clear. Best for: post-Series C/D companies with employee retention pressure.

Broker-led tender (platform)

EquityZen, Forge, Hiive, Carta X. They aggregate sellers, find buyers, handle paperwork. Pros: liquidity for hard-to-place stock. Cons: 3-7% fee; price often below direct sale; some companies refuse to honor platform-led transfers (ROFR, non-transferable language); signaling.

EquityZen: typically founder/early-employee focused, 5% buyer-side + 5% seller-side fee historically.
Forge: marketplace + custodian; institutional-friendly.
Hiive: aggressive marketplace; live order book.
Carta X: cap-table-native; smoother on companies that use Carta.

Forward contract / prepaid forward

Seller "agrees to sell" specific shares at IPO/exit; receives upfront cash today (typically 60-80% of current secondary value). Triangulating tax + risk + cash today.

Pros: cash now, may preserve QSBS clock (tax-treatment depends on contract structure).
Cons: legal complexity, if company stays private longer than expected the math gets ugly, downside if exit price is lower than expected.
Use only with: experienced lawyer + tax advisor + clear understanding of contract treatment for QSBS / LTCG / capital-gain timing.

Share-pledge loan

Borrow against shares (Equitybee, Esofund, Quid). Not a sale — debt collateralized by equity.

Pros: keeps upside, no immediate tax event, immediate liquidity.
Cons: interest cost, margin-call-style triggers if valuation drops, gives lender claim on shares.

Company buyback

Company repurchases. Sometimes at a discount, sometimes at fair-market 409A. Cleanest legally — no ROFR friction.

Pros: no platform fee, often fast, no signaling to outside market.
Cons: company sets the price; rarely the highest clear available; uses balance-sheet cash.

Approvals

The actual hard part of most secondaries is coordination, not pricing.

Right of first refusal (ROFR)

Standard. Company has 15-30 days to match the offer; investors get a second look after that. Sequence:

Term sheet from buyer.
Notice to company. ROFR window starts.
Company decides: exercise, waive, decline.
If declined / waived → notice to investor co-sale and ROFR rights.
Investors decide.
If all waived → close transaction.

ROFR exercise can stop a sale cold. Practical: most companies waive if the buyer is a friendly investor; many exercise selectively for high-quality secondary buyers they want to bring on cap table.

Co-sale right

Investors with co-sale rights can join the sale pro-rata to their stake. If you're selling 1000 shares and a Series A investor has 10% pro-rata, they can sell 100 shares alongside (effectively reducing your slot). Read carefully — co-sale is often pro-rata of fully-diluted, not of the seller's stake.

Board approval

Most certificates require board approval for transfer. Practical: board will rubber-stamp small employee transfers (under 10% of holdings); will scrutinize founder transfers; will sometimes block aggressive secondary requests during sensitive periods (mid-fundraise, M&A talks).

Transfer restriction language

Read the original stock purchase agreement and the operating stockholders' agreement. Look for:

"No transfer without board approval and investor approval" — common
"First-refusal-then-co-sale" — common
"Lockup until [event]" — sometimes
Specific founder restrictions (often more onerous)
"Permitted transferees" carveouts (family trusts, LLCs) — useful for tax planning

Investor approval / waiver

Some agreements require investor (typically Series-X majority) approval of any secondary above a threshold. Practical: if the secondary buyer is a current investor, this is usually frictionless; if the buyer is unknown or competitive to existing investors, this is the hard veto point.

Tax planning

Critical and almost always under-thought-out.

Holding period and LTCG

Federal LTCG: shares held >12 months from acquisition date, taxed at 15-20% + NIIT 3.8% = 18.8-23.8% federal.
STCG (held ≤12 months): ordinary rates, up to 37% federal + NIIT 3.8%.
Watch start of holding period:
- Restricted stock with 83(b) filed: holding period starts at grant.
- Restricted stock without 83(b) (ordinary rates on vest): holding period starts at vest.
- ISO exercise → sale: holding period starts at exercise date.
- NSO exercise → sale: holding period starts at exercise date.
- RSU vest → sale: holding period starts at vest date.
Always confirm cost basis and acquisition date with the company / cap-table custodian before pricing the sale.

QSBS Section 1202 exclusion

Federal exclusion of up to $10M (or 10× basis, whichever is greater) of LTCG on Qualified Small Business Stock. Requirements:

Stock must be in a domestic C-corp at time of issuance.
Company gross assets ≤$50M when issued.
Stock issued directly (not bought from another shareholder; secondary purchases generally don't qualify for QSBS).
Held ≥5 years.
Active business test (≥80% of assets used in active business).
Per-issuer limit: max(10× basis, $10M).

For founders / early employees who got original-issue stock and held 5+ years: this is often the difference between 23.8% federal tax and 0% federal tax on first $10M of gain. Coordinate sale to occur after 5-year mark if possible.

State QSBS treatment varies wildly: California disallows the federal exclusion (must pay full state rate); New York conforms (federal exclusion flows through); Massachusetts conforms; Texas / Washington / Florida have no state income tax (moot). Re-domiciling pre-sale is sometimes done aggressively — talk to a tax lawyer.

AMT trap on ISO exercise

If seller exercised ISOs in a prior tax year and is now selling, check whether there was an AMT preference item from exercise. AMT credit may be partly recoverable. Don't ignore this — a forgotten AMT bill can be 20-28% of the bargain element.

Section 1045 rollover

If holding QSBS <5 years, gains can be rolled into new QSBS within 60 days, preserving the 5-year clock. Niche but useful in repositioning.

State of residence

Sale is taxed in seller's state of residence at time of sale. California: 13.3% top rate. New York: ~10.9%. Florida / Texas / Washington / Nevada / Tennessee / South Dakota: 0%. A move 6-12 months pre-sale is sometimes worth it for a $5M+ gain. CA aggressive on residency tests; document carefully.

Founder-relationship math

Often more important than price.

Signaling

Founder selling 5-15% of holdings during a healthy growth round: usually fine, sometimes positive (founder de-risk = better-aligned long-term focus).
Founder selling 30%+ holdings: red flag for new investors.
Founder selling immediately before a fundraise: avoid; signals reduced confidence.
Founder selling at flat or down-round price: deeply negative signal.

Board / investor optics

Tell the board first. Find out objections early.
Frame as "long-planned, modest amount, life event."
Offer to coordinate with company tender window if one is planned.
Avoid: surprise transactions, secondary above the latest 409A by a lot, sales to competitors.

Co-founder optics

Equal treatment: if one founder sells, the other usually wants to too. Coordinate.
Disproportionate sale: damages co-founder trust. Often worth bringing the other in.

Employee optics

Founders selling while employees are illiquid creates resentment. Best practice: combine with company-led employee tender. If no tender exists, push for one.

Red-flag signals from buyers

Cap-stack quirks: requests for board observer rights, MFN clauses, preference rights — secondary buyer should not be getting governance rights for a secondary.
Side-letter requests: any side letter is a red flag.
Aggressive carve-outs: indemnity demands beyond reps & warranties on share ownership.
"Reps & warranties insurance for secondary": uncommon and adds 1-2% cost; usually unnecessary.
Buyer using SPV: ask who's behind the SPV; if it's a fund-of-funds, fine; if it's a syndicate of unknowns, slow down.
Last-minute price drop ("we found something in diligence"): leverage play. Don't capitulate without re-running price discovery.

Workflow

Run this in 3 phases.

Phase 1: Eligibility and prep (week 1-2)

Pull stockholders' agreement, stock purchase agreement, option grants. Read transfer-restriction language line-by-line.
Confirm vesting status, cost basis, holding-period start dates, 83(b) status.
Confirm QSBS status with company CFO / counsel (5-year clock, $50M asset test at issuance).
Estimate after-tax proceeds at multiple price points (gross sale → STCG/LTCG → state → AMT → net).
Identify co-sale and ROFR mechanics (who, how much, what window).
Talk to a tax advisor before pricing. State of residence matters.

Phase 2: Pricing and buyer search (week 2-6)

Triangulate price using all anchors (last round, 409A, recent trades, forward expectation).
Identify 3-5 likely buyer types and reach out (existing investors first, then growth funds, then platforms).
Get 2-3 firm IOIs before signaling commitment.
Negotiate price + ROFR-waiver coordination upfront.
Frame to the board / company: timing, amount, buyer identity.

Phase 3: Approval and close (week 6-12)

File ROFR notice. Wait the window.
Coordinate co-sale waivers / participation.
Sign purchase agreement; close with company / transfer-agent assistance.
File appropriate tax forms (Schedule D, Form 8949; for QSBS, attach statement).
Monitor for any post-close 409A reset (sometimes a secondary trade resets 409A for the company).

Anti-patterns to flag explicitly

Selling on signaling-bad timing. Avoid mid-fundraise sales unless coordinated with the round.
Selling without QSBS analysis. Million-dollar mistake for many founders.
Pricing on 409A. That's a floor, not a market.
Ignoring co-sale. Assuming you can sell 1000 shares when investors take 30% pro-rata leaves you with 700.
Leaving cash on the table for "speed". The 4-week wait often clears 15% more.
Selling all in one shot. Consider phased sales over 12-24 months for diversification + price-averaging.
Buyer-set timeline. If buyer is rushing, that's their problem; don't bypass diligence on your side (cost basis errors compound).

Integration with other coaches

saas-acquisition-prep-coach: full company sale, not secondary.
pre-seed-fundraising-coach: primary capital raise, not secondary.
equity-comp-negotiation-coach: getting the equity in the first place.
term-sheet-negotiation-coach: primary preferred-round terms.
accelerator-application-coach: pre-revenue program, different stage.

This skill assumes the founder/seller already has equity worth selling. Use it after primary fundraising is sorted, when liquidity becomes a near-term question rather than an "if we exit" abstraction.